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Available online 24 August 2016Background: Synthesized aminocoumarins are heterocyclic compounds possessing potential for the treatment of
insulin-dependent diabetes mellitus with unexplored anti-glycative action.
Results: In this study 4-aminocoumarin derivatives (4-ACDs) were evaluated in vitro for antiglycation (AG)
activities by using the human serum albumin (HSA)/glucose system, for 8 weeks of incubation. The glycation
and conformational alteration of HSA in the presence of the tested compounds were evaluated by Congo
red assay, ﬂuorescence and circular dichroism spectroscopy. The antioxidant (AO) capacity were also tested
by four different assays including: DPPH (2,2′-diphenyl-1-picrylhydrazyl radical), ABTS (2,2-azinobis
(3-ethylbenzothiazoline-6-sulphonate) diammonium salt), FRAP (ferric reducing antioxidant power) and
β-carotene-linoleic acid assay. The tested compounds showed AG and AO effects. The intensity of the
accomplished AO potential is related to the type of the used assay. Signiﬁcant alterations in the secondary
(monitored by CD spectropolarimetry) and tertiary structure (assessed by spectroﬂuorimetry) of HSA upon
glycation were mitigated by the 4-ACDs, suggesting their suppressive role in the late stage (post-Amadori) of
the HSA glycation.
Conclusions: By the analogues, in vitro ascertained AO and AG properties of 4-ACDmay be recognized as rationale
for their protective role against oxidative changes of proteins, thereby precluding diabetic complications in
humans.
© 2016 Pontiﬁcia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. All rights reserved.
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Coumarins are heterocyclic compounds, naturally occurring in
green plants, fungi, bacteria and some fruits. An antioxidant and
anti-inﬂammatory properties of coumarins and their derivatives have
recognized to reduce the risk of cancer, diabetes, cardiovascular
and brain diseases [1]. Moreover, in vitro inhibitory properties
of 4-aminocoumarin derivatives (4-ACD) against human platelet
aggregation, antioxidant, anticancer, antimicrobial and anti-mycobacterial
activity have been described [2,3]. Likewise, cyclic 4-aminocoumarin
derivatives have been reported to act on the viability of HepG2r Biology Division, Department
yahoo.com (M. Miroliaei).
idad Católica de Valparaíso.
araíso. Production and hosting by Elscells through antioxidant activity [3]. Recently, antioxidant effect of
coumarins was recognized as their novel mechanisms of action [4].
Increased content of free radicals (FRs) in living organisms occurs
due to their increased production or insufﬁcient sequestration by the
innate antioxidative defense system (AODS). Free radicals initiate
oxidative stress (OS), i.e. oxidative injury of all classes of biomolecules
(proteins, lipids, DNA). This pathophysiological mechanism has been
documented in major ailments such as diabetes, carcinogenesis,
atherogenesis, aging, etc. [5,6]. Protein glycation occurs spontaneously,
but increasingly in the presence of oxidizing agents such as FRs.
Glycated proteins are involved in long term complications of diabetes
[7,8]. Reduced antioxidant status coexistence with hyperglycemia
results in formation of heterogeneous molecules complexes known
as advanced glycation end products (AGEs) [9]. Cytotoxicity of
AGE adducts have been hypothesized to be tightly intertwined with
OS [10,11]. Metal-catalyzed oxidation reactions were also found toevier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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both antioxidant and antiglycation (anti-glyoxidants) properties
would be ideal candidates to suppress harmful effects caused by FRs in
biological systems, as well as to obstruct the AGE-formation-based
mechanism — pathways in diabetic patients. Recently, we reported
that anti-AGE activity of balm extract was associated with its
antioxidant properties [12]. Madhu and Devi demonstrated that OS
was diminished by vitamins C and E intake in diabetic rats [13].
Moreover, it has been found that the hemoglobin glycation decreases
with the supplement of vitamin C in the diabetic patient [14].
Current efforts have being made to synthetize coumarin modiﬁed
analogs with better antioxidant properties and reduced adverse
effects. In a previous paper, 4-hydroxycoumarin-3-carboxamide
derivatives have been synthesized as potential drugs for the treatment
of insulin-dependent diabetes mellitus [6]. The objective of this study
was to evaluate if synthesized 4-ACDs exhibit antioxidant properties
and if it is associated with antiglycemic activity.
2. Materials and methods
2.1. Chemicals
2,2-Azinobis(3-ethylbenzothiazoline-6-sulphonate) diammonium
salt (ABTS), ascorbic acid, β-carotene, 2-deoxy-D-ribose, 2,2′-diphenyl-
1-picrylhydrazyl (DPPH), disodium salt of ethylenediamine
tetraacetic acid (EDTA), ferrozine, Folin–Ciocalteu reagent, gallic
acid, hypoxanthine, iron(III) chloride, iron(II) chloride, linoleic
acid, potassium hexacyanoferrate, trichloroacetic acid (TCA),
Trolox, human serum albumin (HSA) and glucose were from Sigma
Chemical Company (Germany).
2.2. Synthesized/tested compounds: analogues of 4-aminocoumarin
Three 4-ACDs were synthesized and diluted in relation to their
water solubility [3 mg/mL], according to Ivanov et al. [15]: N-{2-[(2-
oxo-2H-chromen-4-yl)amino]ethyl}acetamide or aminoethylacetamide
(1), 4-[2-hydroxypropyl)amino]-2H-chromen-2-one or aminoalcohol
(2) and N-{2-chromen-4-yl)ami-no]propyl}acetamide or
aminopropylacetamide (3) [15] (Scheme 1).
2.3. In vitro antioxidant potential measurements
2.3.1. DPPH free-radical scavenging activity
The DPPH assay is based on the ability of an antioxidant [16]
to donate hydrogen to DPPH radical (DPPH•). The change in color
of DPPH• (from purple to yellow) is the measure of free radical
scavenging activity. The hydrogen-donating activity of the 4-ACDs
was measured according to the method by Gyamﬁ et al. [17]. By
accepting hydrogen (H+ and e-), purple-colored DPPH• is being
converted into the non-radical form (DPPH-H), yellow-colored
diphenylpicrylhydrazine. Brieﬂy, 50 mL of dissolved 4-ACDs wasO O
NH
NH
O
O O
NH
O
aminoethylacetamide (1)   aminoalcoho
Scheme 1. Structures ofmixed with 450 mL of Tris–HCl buffer (50 mmol/L, pH 7.4) and
1 mL of (0.1 mmol/L) DPPH• (dissolved in methanol). After 30 min,
the absorbance was recorded at 517 nm (absorption max for DPPH•).
The percentage of inhibition was calculated using [Equation 1] and the
concentration of the compound at which it exhibits 50% inhibition
(IC50) value was estimated using a non-linear regression algorithm.
Percentage inhibition
¼ Abscontrol−Abssample
 
=Abscontrol
  100
½Equation 1
2.3.2. ABTS•+ free-radical scavenging activity
The antioxidant capacity of the tested compounds was estimated
by the method of Re et al. [18]. The blue/green colored ABTS•+
solution used for the measurement of 4-ACDs antioxidative activities
was prepared by mixing ABTS (10 mL of 7 mmol/L) with oxidizing
agent K2S2O8 (5 mL of 2.45 mmol/L) for 12–16 h in the dark and
subsequently diluted with ethanol (a dilution of between 1/50 and
1/400 was performed in order to obtain absorbance value of 0.700, at
734 nm). The reduction of the radical cation (ABTS•+) by 4-ACDs was
determined as decolorization at 734 nm, i.e. the percentage inhibition
of absorbance of the ABTS•+ solution (since 1 min upon mixing of
1.5 mL of the prepared ABTS•+ solution with 15 μL of 3 mg/mL4-ACDs
samples, at 5 min intervals, for 40 min).
The results are expressed as the Trolox equivalent antioxidant
capacity (TEAC, mmol/L Trolox) at different time intervals.
2.3.3. FRAP (ferric reducing antioxidant power) assay
The principle of this assay is based on one-electron reduction of
Fe (III)/ferricyanide complex to the ferrous form Fe (II) [19]. In brief,
1 mL of 3 mg/mL compound was mixed with 2.5 mL of phosphate
buffer (0.2 mol/L, pH 6.6) and 2.5 mL of a 10 g/L K3Fe(CN)6, and
incubated at 50°C, for 30 min. After the incubation, 2.5 mL of a 100 g/L
TCA solution was added to terminate the reaction and the mixture
was centrifuged for 10 min (1800 rpm). Finally, 2.5 mL of supernatant
was used to mix with 2.5 mL ultra-pure water and 0.5 mL of a 1 g/L
FeCl3. The absorbance was recorded at 700 nm and the data were
presented as ascorbic acid equivalents (AscAE; mmol ascorbic acid/g
sample).
2.3.4. β-Carotene-linoleic acid bleaching inhibition
The determination of antioxidant activity was evaluated by the
ability of the compounds to inhibit the bleaching of the β-carotene
by linoleic acid. Namely, during the incubation at 50°C linoleic acid
produces peroxyl radical which becomes neutralized by the presence
of antioxidants, at the same time the β-carotene oxidation is avoided
(i.e. inhibition of β-carotene bleaching occurs, thus yellow color
of β-carotene in the system persists in the presence of antioxidant)
[20]. Brieﬂy, 0.2 mg β-carotene dissolved in 1 mL chloroform, 20 mg
of linoleic acid and 200 mg of Tween 20 were transferred into a
round-bottom ﬂask. Once the chloroform had been removed underH
O O
NH
NH O
l (2) aminopropylacetamide (3)
tested compounds.
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mixture was stirred for 30 min. Five mL aliquots of the emulsion were
mixed with either 200 mL of dissolved compounds or 200 mL of
positive controls (1 mg/mL) and measured at 470 nm twice, before
and after the 2 h incubation in a water bath at 50°C for 2 h. The
data were presented as a percentage of an antioxidant activity %
(AA %), using [Equation 2]:
AA% ¼ 1− Abs0sample−Abs120 sample
 
= Abs0control–Abs120 controlð Þ
 
 100
½Equation 22.4. Antiglycation potential of the tested compounds: in vitro measurements
2.4.1. Preparation of the glycated HSA
The stock solution of 4 mg HSA/mL [prepared in 50 mM phosphate
buffer (pH 7.4)] was mixed with equal volume of 100 mM glucose
solution (dissolved in the same buffer) to gain a ﬁnal concentration of
2 mg/mL HSA and 50 mM glucose. Samples (50 mL of 2 mg/mL HSA
as control and 50 mL of 2 mg/mL HSA with 50 mM glucose) were
pre-incubated in the presence and absence of each of the synthetic
compounds. All samples were sterile-ﬁltered with a 0.22 μmmillipore
ﬁlter and incubated in capped vials at 37°C for up to 8 weeks.
Unbound glucose molecules were removed from HSA by exhaustive
dialysis against 50 mM phosphate buffer pH 7.4 and stored at 4°C
prior to analysis.
2.4.2. Congo red binding assay
Congo red binding to amyloid cross-β structure of HSA was
performed by Klunk et al. method [21]. The absorbance of the formed
complex was measured at 530 nm. Brieﬂy, 500 μL of each sample (HSA,
glycated HSA with and without each compound) were incubated with
100 μL of Congo red (100 μM) in PBS with 10% (v/v) ethanol for 5 min
at room temperature and afterwards, the absorbance of the reaction
mixture was measured.
2.4.3. Intrinsic ﬂuorescence measurements
Intrinsic ﬂuorescence spectra of native and glycated-HSA, incubated
with 50mMglucose in the presence and absence of the coumarinswere
collected. Both, native and glycated-HSA were excited at 270 nm,
and the spectra were corrected for buffer baseline ﬂuorescence. The
glycation of HSA was also conﬁrmed by AGE-related auto-ﬂuorescence
assay. Fluorescence of relevant samples (0.15 mg/mL) was measured
after exciting at 270 nm, and monitoring the emission at 295–450 nm
using a Hitachi F-2500 spectroﬂuorometer. Correction for spectra was
done with the appropriate protein and buffer blanks.
2.4.4. Circular dichroism (CD) spectropolarimetry
All far-UV CD spectra of the mixtures of the tested compounds
with HSA-GA, and HSA were recorded in the far-ultraviolet region
(190–250 nm) using solutions with a protein concentration of about
0.15–0.2 mg/mL. Experiments were performed on a 215 Aviv
spectropolarimeter (USA) and measuring parameters were set as
follows: bandwidth: 1 nm, response time: 2 s; scan speed: 20 nm/min;
and resulted spectra is an average of four scans; baseline was
corrected for the respective blanks. Results are expressed as molar
ellipticity, [Ө] deg·cm2 dmol-1, based on a mean amino acid residue
weight (MRW).
3. Statistical analysis
One-way ANOVA and Tukey's post hoc multiple test was used
(software GraphPad version 5) for statistical data analysis. Values are
presented as the means ± standard deviation. Correlation coefﬁcients
were calculated using the Spearman's test. Differences were considered
statistically signiﬁcant for p b 0.05 for all tests [31].4. Results and discussion
Three 4-ACDs (compounds 1–3) were evaluated in vitro for
the potential antioxidant properties. We attempted to clarify if the
structurally different side chains of the 4-ACDs interfere with their
antioxidative and/or antiglication activities.
Due to known limitations of the in vitromethods [22], the antioxidant
capacity of the tested compounds wasmeasured by four different assays
including: DPPH and ABTS radical scavenging activities, iron (III)
reduction power and inhibition of β-carotene-linoleic acid bleaching
assay. Achieved antioxidant activities closely depend to the applied
assays and is related decisively to the conditions and required red-ox
mechanism patterns, speciﬁcally for the particular test. Thus, obtained
values of the antioxidant capacity for the certain compound differs
according to the applied test. The principles of these measurements
are different and are based on: a) one or two electron(s) transfer
between the particular substrate and tested compound (FRAP assay);
b) hydrogen radical (H•) donating to certain substrate (ABTS• and
DPPH• assays); or c) spearing already present antioxidant (for instance:
β-carotene bleaching assay) [23]. Thus, documented AO activity for
one substance measured by one test does not mean that it will be
accomplished by using another test for the same substance.
The DPPH and ABTS assays were used to test the ability of the
examined 4-ACDs to donate H• and thus neutralize corresponding
reactive radicals (DPPH• and ABTS•+). After H• abstraction from
the enamine group at the position 4 of the coumarin ring, formed
coumarin radical is partially stabilized by resonance and induces
stability [24].
Based on the nitrogen-centered DPPH• assay, only compound-1
showed the free radical scavenging potential, i.e. antioxidative effect
(Fig. 1a), although signiﬁcantly lower than vitamin C (p b 0.0001) [25].
An alternative test that provides good estimation of the
antioxidant ability, applicable for both lipophilic and hydrophilic
antioxidants is ABTS•+ decolourization assay which also enables
spectral interferences [26]. In general, highly pigmented and
hydrophilic antioxidants are better assessed for antioxidant activity
using the ABTS assay compared to the DPPH assay [25]. The ABTS•+
is a moderately stable nitrogen center radical [20] with higher
solubility than DPPH•. Additional advantage of the ABTS assay
is that it can be used in different pH ranges and therefore takes
into consideration the effect of pH on the antioxidant activity of
the tested sample [27]. All of the compounds [3 mg/mL] reached
maximal activity (plateau) at 30 min and to the following intensities:
compound-1 N compound-2 N compound-3 (Fig. 1b).
The results of the ABTS assay should be comparable to the results
obtained by DPPH assay and may be considered as a conﬁrmation of
the DDPH assay, although the absolute values from the ABTS assay
are generally higher [28]. Both radicals (DPPH•, ABTS•+) show the
same stoichiometry with water-soluble vitamin E analogue, Trolox
(e.g., two moles of ABTS•+ [29] or two moles of DPPH radicals [30]
are scavenged by one mole of Trolox).
One of the mechanisms by which antioxidants achieved their
role is related to their reducing potency [26]. For this reason, FRAP
assays were used to measure capability of the compounds to reduce
Fe3+ into Fe2+ in acidic medium, in the presence of e-donors. The
data were presented as ascorbic acid equivalent (AscE) values. All
tested compounds [3 mg/mL] were capable of reducing Fe3+ and
comprised similar reducing potential, around double lower than
vitamin C (Fig. 1c). Having similar effect, we concluded that e-
donating properties of the tested compounds are addressed to the
coumarin part of the molecule, independently of substituents on the
position 4. Keto enol tautomerie might occur in coumarin heterocyclic
part of the molecule and in the amide part. Lactone carbonyl group is
coumarin heterocyclic part which is an electron acceptor. The tested
4-ACDs showed similar redox potential evaluated by FRAP assay,
suggesting that differences in the structure of alkyl radicals in position
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Fig. 1. Antioxidative capacity of 4-aminocumarin derivatives [3 mg/ml] measured by the following assays: (a) DPPH•; (B) ABTS•+; (c) FRAP; (d) beta-carotene bleaching inhibition.
(a): DPPH assay: the results are presented as a percentage of inhibition the absorbance at 517 nm (absorption max for DPPH•); (b) ABTS assay: the results are expressed as the Trolox
equivalent antioxidant capacity (TEAC, mmol/L Trolox) at different time intervals; (c) FRAP assay: the data were presented as ascorbic acid equivalents (AscAE; mmol ascorbic acid/g
sample); (d) β-Carotene bleaching: The data were presented as a percentage of an antioxidant activity % (AA %). Values are presented as means ± S.D. Statistical signiﬁcance was
considered at: *p b 0.05; **p b 0.01; ***p b 0.0001. Labels of statistical signiﬁcance: α: signiﬁcantly different from vit C; £: signiﬁcantly different from compound-1; ¥: signiﬁcantly
different from compound-2.
Fig. 2. Time evolution of the secondary structure alteration of HSA [2 mg/mL HSA and
50 mM glucose] by Congo red assay. Values are presented as means ± S.D. Statistical
signiﬁcance was considered at: *p b 0.05; **p b 0.01; ***p b 0.0001.Labels of statistical
signiﬁcance: α: signiﬁcantly different from HSA; §: Signiﬁcantly different from G-HSA.
The values are expressed as average ± STDEV and represented plateau (reached
6–10 weeks).
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tested compounds [3 mg/mL] accomplished almost double lower AO
activity compared to vitamin C (p b 0.0001).
What guided us to try β-carotene–linoleic bleaching inhibition
assay was the ﬁnding that the side chain in the 4-ACDs was the
reason for increased lipophilicity and lower reducing potential than
hydrophilic vitamin C. Considering that lipo- or hydro-philicity of
4-ACDs may interfere with AO respond, we employed additionally a
membrane-based lipid peroxidation model, using β-carotene-linoleic
bleaching inhibition assay to test if the examined compounds [3 mg/mL]
may prevent/inhibit lipid peroxidation [28]. A membrane-based lipid
peroxidation model, using β-carotene-linoleic bleaching inhibition assay
offers a good biologically relevant matrix compared to DPPH and ABTS
free-radical scavenging assays. Brieﬂy, in this system, linoleic acid in an
oil–water emulsion phase undergoes thermally induced oxidation,
thereby producing free radicals which react with the β-carotene's
chromophore, resulting in a bleaching effect [20]. Only compound-3
showed AO activity, by using the β-carotene bleaching test, what is in
accordance with side chain length, although only 30% of vitamin C
activity (p b 0.0001) (Fig. 1d). It is known that lipophilicity increases
with the CH length increase for approximately 0.5 (log p = [comp]
org/[comp] H2O) [25].
Diabetes is an oxidative stress-associated disease, thus the
long-term complications in diabetes may partially be reduced by
taking antioxidants. To examine if the 4-ACDs prevent glycation of
proteins in vitro, Congo red binding assay in the HSA/glucose system
[2 mg/mL HSA and 50 mM glucose] was applied. Recently, we have
reported that secondary structure alteration of albumin occurs if
exposed to glucose in vitro [8]. The amount of the secondary structure
alterations due to glycation can be followed by measuring the
absorbance at 530 nm, which reﬂects the intensity of the binding
of the dye to the hydrophobic clefts between anti-parallel β-strands
[21]. All compounds [3 mg/ml] signiﬁcantly inhibited the secondary
structure alterations of HSA, compared to glycated HSA (G-HSA) (forcompounds1–3: p b 0.05 and for compound-2: p b 0.001) (Fig. 2). We
showed that 4-ACDs have potential to prevent glycation of HSA
hindering the transition of α to β conformer of HSA, therefore they
may have a suppressive role in the late stage (post-Amadori) of HSA
glycation. Slightly higher suppressive effect of compound 2 compared
with compounds 1 and 3 on glucose-induced HSA damage may be
prescribed to the hydroxyl group of the side chain i.e. the absence of
acetamide group.
Furthermore, due to the possibility of the tested compounds to
prevent secondary structure alteration of HSA, the HSA-AGE structure
was analyzed in greater detail with CD spectropolarimetry. As
illustrated in Fig. 3, a large alteration in the secondary structure of
Fig. 3. Far-UV CD spectra of native HSA and glycated HSA [2 mg/mL HSA and 50 mM
glucose] in the presence and/or absence of the 4-aminocumarin compounds [3 mg/mL].
CD data were expressed as molar ellipticity (deg cm2 dmol-1).
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from AGE formation studies suggests the appearance of cross-β
structures of proteins as a unique recognition signal for globular
protein structures changes upon glycation [29]. We showed that the
aminocoumarins profoundly prevent the structural changes caused
by D-glucose, keeping the protein molecule close to its native polar
conformation. The tested compounds [3 mg/mL] have potential to
keep proteins in α-conform by concealing the glycation sites and
lowering the extent of the solvent-accessible surface area, thereby
producing barriers for cross β-structure formation.
Oxidative stress in diabetes is coupled with the formation of AGEs
within non-enzymatic glycation reactions [27]. In order to evaluate
the ability of used compounds [3 mg/mL] to prevent AGE formation,
autoﬂuorescence measurements were performed. The glycophore
ﬂuorescence (λex, 280 nm) spectra of albumin-AGE preparations
(0.15 mg/ml) were recorded and compared with those in the
presence of the synthesized coumarins [3 mg/mL]. Fluorescence
intensity at 295–445 nm was decreased in the glycated sample (Fig. 4)
and retained to be reduced upon the treatment with the tested
compound-2. The two other compounds failed to protect HSA
conformational alteration under the glycation. The molecular basis for
this effect appears to be linked with hydroxyl group of compound-2
hindering the incorporation of albumin with C1′–OH of glucose,
thereby interfering with Schiff base formation and the subsequent
Amadori reaction.Fig. 4. Fluorescence spectra of glycated HSA (0.15 mg/mL). Spectra were obtained in the
wavelength range of 295–445 nm after excitation at 270 nm in the presence and/or
absence of the compounds [3 mg/mL].5. Conclusion
In summary, we showed that in vitro tested 4-ACDs achieved
moderate antioxidant effect (comparing with vitamin C) and
antiglycant activity, indicating their possible protective role against
oxidative biomolecule damage in vivo. We showed that antioxidant
properties of the tested compounds correlate inversely with
antiglycant activity. Compound-2 accomplished stronger antiglycant
activity than compounds 1–3, but weaker antioxidative effect and vice
versa. We demonstrated that substituents on the position 4 of the
aromatic ring of the tested coumarins inﬂuence antiglycant activity.
Observed moderate antioxidant effects of the 4-ACDs along with
antiglycant properties should be considered as rationale for further in
vivo investigation related to their potentially preventive/protective
role in diabetes.
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